Mnemonic for direct sympathomimetic catecholamines
Direct sympathomimetic catecholamines mnemonic DINED: Dopamine Isoproterenol Norepinephrine Epinephrine Dobutamine Thanks to MedExcel
Pharmacokinetics video animation. IV administration.
Recommended pharmacokinetics reading Pocket Guide: Pharmacokinetics Made Easy (2009) Basic Clinical Pharmacokinetics (2009) Concepts in Clinical Pharmacokinetics (2010) Clinical Pharmacokinetics, 4th Edition (2008)
Sitaxentan (Thelin) for pulmonary hypertension. Australian Prescriber review
From Australian Prescriber: Sitaxentan sodium Thelin (CSL) 100 mg tablets Approved indication: pulmonary hypertension Australian Medicines Handbook section 6.7.2 Pulmonary hypertension results from intimal hypertrophy narrowing small pulmonary arteries. The increase in pulmonary vascular resistance leads to right ventricular failure. Primary pulmonary hypertension is less common than the pulmonary hypertension associated with other conditions such […]
Pharmacokinetics video. Absorption of drugs by oral route
More information about the oral route of drug administration: Oral (p.o.) Ingestion a. Convenient route for administration of solid as well as liquid formulations.
Second messenger system animation. IP3 signal transduction pathway
Created by Department of Biology, Davidson College, Davidson, NC 28036 More information about inositol trisphosphate from the WIkipedia article about IP3 : Inositol trisphosphate or inositol 1,4,5-trisphosphate (also commonly known as triphosphoinositol; abbreviated InsP3 or IP3), together with diacylglycerol, is a secondary messenger molecule used in signal transduction in biological cells. It is made by […]
Pharmacodynamics definitions. Receptor desensitization
The following pharmacological definition has been taken from the Pharmacology and Experimental Therapeutics Department Glossary at Boston University School of Medicine. Desensitization: A decline in the response to repeated or sustained application of an agonist that is a consequence of changes at the level of the receptor. The copyright of the text is hold by […]
Degarelix (Firmagon) for prostate cancer: now approved by FDA
Related to EMEA’s positive opinion on degarelix (Firmagon) for prostate cancer, FDA issues this press release dated Dec. 29, 2008: FDA Approves Drug for Patients with Advanced Prostate Cancer The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.
Ibandronic acid (Bondronat) for the treatment of hypercalcaemia and bony metastases. Australian Prescriber review
From Australian Prescriber: Ibandronic acid Bondronat (Hospira) vials containing 6 mg/6 mL Approved indications: hypercalcaemia, bony metastases of breast cancer Australian Medicines Handbook section 10.3.1 Bisphosphonates can reduce the hypercalcaemia of malignant disease by inhibiting the resorption of bone. Clodronate, pamidronate and zoledronic acid are already available for this indication. They are now
Pramipexole (Sifrol): dopamine agonist for the treatment of Parkinson’s disease
From Australian Prescriber: Pramipexole Sifrol (Boehringer Ingelheim) 125 microgram, 250 microgram and 1 mg tablets Approved indications: Parkinson’s disease, restless legs syndrome Australian Medicines Handbook section 16.2.1
Duloxetine (Cymbalta, Yentreve): a serotonin-norepinephrine reuptake inhibitor for major depression. Australian prescriber review
From Australian Prescriber: Duloxetine Cymbalta (Eli Lilly) 30 mg and 60 mg capsules Approved indication: major depression Australian Medicines Handbook section 18.1.2 Duloxetine is a new antidepressant which selectively inhibits serotonin and noradrenaline reuptake. It also weakly inhibits dopamine uptake. (See details of its mechanism of action)
Temsirolimus (Torisel): kinase inhibitor for the treatment of advanced renal cell carcinoma. Australian Prescriber review
From Australian Prescriber: Temsirolimus Torisel (Wyeth) vials containing 25 mg/mL concentrate Approved indication: advanced renal cell carcinoma Australian Medicines Handbook section 14.2.3 About 30% of patients with renal cell carcinoma have advanced or metastatic disease at the time of diagnosis. Chemotherapy is generally ineffective and nephrectomy is the mainstay of treatment for disease confined to […]
Paricalcitol (Zemplar): a vitamin D analogue for the treatment of secondary hyperparathyroidism. Australian Prescriber review
From Australian Prescriber: Paricalcitol Zemplar (Abbott) 1 microgram, 2 microgram and 4 microgram capsules 5 microgram/mL in 1 mL and 2 mL ampoules Approved indication: secondary hyperparathyroidism Australian Medicines Handbook section 10.3.2 In chronic renal failure there is reduced production of calcitriol, the active form of vitamin D. This affects calcium homeostasis and leads to […]
Panitumumab (Vectibix) for metastatic colorectal carcinoma. Australian Prescriber review
From Australian Prescriber: Panitumumab Vectibix (Amgen) vials containing 20 mg/mL in 5 mL, 10 mL or 20 mL volume Approved indication: metastatic colorectal carcinoma Australian Medicines Handbook section 14.2.1 Panitumumab is a humanised monoclonal antibody for the treatment of metastatic colorectal carcinomas expressing the epidermal growth factor receptor. It is indicated for patients whose tumours […]
Anti-thymocyte globulin (Thymoglobuline) for renal transplant rejection and aplastic anaemia. Australian Prescriber review
From Australian Prescriber: Anti-thymocyte globulin Thymoglobuline (Genzyme) vials containing 25 mg freeze-dried powder Approved indication: renal transplant rejection and aplastic anaemia Australian Medicines Handbook section 14.5.3 Anti-thymocyte globulin is indicated for the prophylaxis of renal graft rejection as well as the treatment of steroid-resistant renal transplant rejection. Kidney transplantation is the treatment of choice for […]